logo
  

Argenx Submits BLA To FDA For Subcutaneous Efgartigimod For Generalized Myasthenia Gravis Treatment

argenx SE (ARGX) said that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for Subcutaneous efgartigimod (1000mg efgartigimod-PH20) for the treatment of generalized myasthenia gravis (gMG) in adult patients.

The submission was based on positive data from the Phase 3 ADAPT-SC trial demonstrating noninferiority of subcutaneous efgartigimod compared to intravenously administered VYVGART (efgartigimod alfa-fcab) based on total immunoglobulin G or IgG reduction at day 29.

Efgartigimod is an antibody fragment designed to reduce pathogenic immunoglobulin G (IgG) antibodies by binding to the neonatal Fc receptor and blocking the IgG recycling process. Efgartigimod is being investigated in several autoimmune diseases known to be mediated by disease-causing IgG antibodies, including neuromuscular disorders, blood disorders, and skin blistering diseases, in both an intravenous and subcutaneous (SC) formulation.

Generalized myasthenia gravis (gMG) is a rare and chronic autoimmune disease where IgG autoantibodies disrupt communication between nerves and muscles, causing debilitating and potentially life-threatening muscle weakness.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Stocks fluctuated in morning trading on Friday before once again coming under pressure over the course of the afternoon. The major averages extended the sharp pullback seen on Thursday, ending the session at their lowest closing levels since late 2020. Consumer sentiment in the U.S. improved by less than initially estimated in the month of September, according to revised data released by the University of Michigan on Friday. The University of Michigan said the consumer sentiment index for September was downwardly revised to 58.6 from the preliminary estimate of 59.5. Chicago-area business activity unexpectedly contracted in the month of September, according to a report released by MNI Indicators on Friday. MNI Indicators said its Chicago business barometer slumped to 45.7 in September from 52.2 in August, with a reading below 50 indicating contraction. Economists had expected the business barometer to edge down to 51.8.
RELATED NEWS
Follow RTT